In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner.
Today it's the quarter-final stage, and LINN Energy takes on Isis Pharmaceuticals in our search for the better stock.
Joel South, energy analyst at The Motley Fool, thinks LINN Energy (NASDAQ:LINE) is the premier upstream MLP and worthy of your investment. LINN offers a top-tier distribution yield of 9.7% and management continues to execute on its strategy of acquiring mature oil and gas assets that are operated strategically to increase cash flow and return excess cash to unitholders.
David Williamson, Motley Fool health-care analyst, thinks Isis Pharmaceuticals (NASDAQ:IONS) should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of Big Pharma members have struck partnership deals with Isis. The company already has orphan drug Kynamro on the market, and it has also seen recent success from a midstage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Do you know this energy tax "loophole"?
You already know record oil and natural gas production is changing the lives of millions of Americans. But what you probably haven't heard is that the IRS is encouraging investors to support our growing energy renaissance, offering you a tax loophole to invest in some of America's greatest energy companies. Take advantage of this profitable opportunity by grabbing your brand-new special report, "The IRS Is Daring You to Make This Investment Now!," and you'll learn about the simple strategy to take advantage of a little-known IRS rule. Don't miss out on advice that could help you cut taxes for decades to come. Click here to learn more.
Vote here to determine the winner of this match and sound off in the comments box below. Check back to Fool.com to see who advances in the tournament.
Joel South has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.